Engineered CAR T Cells Show Promise in Targeting Bladder Cancer in Mouse Studies

Engineered CAR T cell therapy has demonstrated efficacy in targeting bladder cancer in preclinical mouse models, according to a study published in Nature Cancer. The research, conducted by a team at the University of California, San Francisco (UCSF), represents a potential breakthrough in immunotherapy for a disease that affects over 80,000 people annually in the U.S., according to the American Cancer Society.

How CAR T Cell Therapy Works

Chimeric antigen receptor (CAR) T cell therapy involves modifying a patient’s own T cells to recognize and attack cancer cells. In the study, researchers engineered T cells to target a protein called B7-H3, which is overexpressed in bladder cancer. The modified cells were then tested in mouse models with human bladder tumors.

“The approach selectively targeted cancer cells while sparing healthy tissue, which is a critical challenge in oncology,” said Dr. Emily Chen, a senior author of the study and a hematologist-oncologist at UCSF. “This suggests a pathway for more precise treatments.”

Results and Implications

The therapy reduced tumor size by 70% in 80% of the mice tested, with no significant toxicity observed. The findings align with earlier research on CAR T cells for other cancers, such as leukemia and lymphoma, but represent the first successful application to bladder cancer in animal models.

Bladder cancer is often resistant to traditional immunotherapies like checkpoint inhibitors, leaving patients with limited options. The study’s lead researcher, Dr. Michael Torres, emphasized the need for further testing. “These results are encouraging, but we must confirm safety and efficacy in human trials before considering this a treatment option,” he stated.

Challenges and Next Steps

While the study highlights the potential of CAR T therapy, several hurdles remain. Manufacturing personalized T cells is costly and time-consuming, and the long-term effects of such treatments are not yet fully understood. Additionally, bladder cancer’s heterogeneity—meaning tumors vary widely in molecular makeup—could limit the therapy’s effectiveness across all patients.

The National Cancer Institute (NCI) is funding phase I clinical trials to evaluate B7-H3-targeted CAR T cells in humans, with results expected by 2025. “If these early results translate, it could redefine how we treat advanced bladder cancer,” said Dr. Laura Kim, an NCI spokesperson.

What Patients Should Know

For now, the therapy remains in preclinical stages. Patients with bladder cancer should consult their oncologists about current standard treatments, including surgery, chemotherapy, and FDA-approved immunotherapies like pembrolizumab (Keytruda).

“This research is a step forward, but it’s not a substitute for existing care,” cautioned Dr. Sarah Lin, a urologic oncologist at Memorial Sloan Kettering Cancer Center. “Patients should stay informed but avoid unproven treatments.”

The study underscores the rapid evolution of immunotherapy, with CAR T cells now being explored for over 30 cancer types. As research progresses, the focus will shift to improving accessibility, reducing costs, and expanding personalized treatment options for patients.